Thank you for donating!

You can donate using the following services.

Niemann-Pick Disease Type C

Overview

Niemann-Pick Type C (NP-C) is a rare inherited neurodegenerative disease that affects infants, children and adults. It is caused by an accumulation of lipids (fats) in the liver, brain and spleen. The age of onset and rate of disease progression can vary greatly from person to person; for example some children develop neurological symptoms early in childhood, whereas others may remain symptom free for a number of years.

It is inherited when two copies of a faulty gene (a mutation) are passed on to a child. In every pregnancy of a couple who each carry a copy of the faulty Niemann-Pick gene, there is a 1 in 4 chance (25%) that their child will have Niemann-Pick disease. This is known as autosomal recessive inheritance.

NP-C is divided into two subtypes, NP-C1 and NP-C2, as each is caused by a different gene mutation. Approximately 95 per cent of NP-C cases are caused by genetic mutations in the NP-C1 gene, with the other five per cent caused by mutations in the NP-C2 gene.

The incidence of NP-C is widely reported at 1  in 120,000, although recent evidence suggests  this may be an under-estimate.

Cause

Niemann-Pick Disease Type C (NP-C) is caused by an accumulation of cholesterol and other fatty substances in the liver, brain and spleen.

Diagnosis

Niemann-Pick Disease Type C (NP-C) is difficult to diagnosis as the symptoms are non-specific to the disease and will vary from person to person. NP-C is diagnosed by taking a small piece of skin (a skin biopsy) to see whether there is accumulation of fatty substances within the cells.

Diagnosis can also be made via a DNA analysis if the mutations in the affected child are known. This can be done fairly simply on a blood test but is only carried out in a few specialist centres.

Symptoms

Symptoms of Niemann-Pick Disease Type C (NP-C) vary with age of onset and from patient to patient.They may include:

  • Jaundice at (or shortly after) birth
  • An enlarged spleen and/or liver (hepatosplenamegaly)
  • Difficulty with upward and downward eye movements (Vertical Supranuclear Gaze Palsy)
  • Unsteadiness of gait, clumsiness, problems in walking (ataxia)
  • Difficulty in posturing of limbs (dystonia)
  • Slurred, irregular speech (dysarthria)
  • Learning difficulties and progressive intellectual decline (cognitive dysfunction/dementia)
  • Sudden loss of muscle tone which may lead to falls (cataplexy)
  • Tremors accompanying movement and, in some cases, seizures
  • Swallowing problems (dysphagia)

 

Treatments

There is no cure for Niemann-Pick Disease Type C (NP-C), although patients benefit from palliative treatments (individual medications that will help to treat the symptoms related to the condition). Occupational therapy can be used to help with posture, speech and movement.

In 2009, the European Medicines Agency approved the use of Zavesca© for the treatment of progressive neurological manifestations in adult and paediatric patients with NP-C.  Zavesca© has been shown to delay the progression and stabilise certain symptoms of the disease. However, this drug is not suitable for every affected individual and you are advised to discuss all medical issues with your doctor.

There are a number of clinical trials currently taking place investigating new therapeutic options for patients with NP-C.

Video Overview

Latest news

13.09.18

NPUK Annual Family Conference & Interactive Workshop 2018 (Preliminary Programme)

The NPUK Annual Family Conference & Interactive Workshop is all set for next weekend, where you will once again get the opportunity to hear the latest developments regarding therapies and clinical trials for ASMD Niemann-Pick disease types A and B, and Niemann-Pick type C, plus related care issues, breakout sessions, and workshops...

Read more

11.07.18

Are you looking forward to the NPUK Annual Family Conference?

We are looking forward to this year's NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases, which will mark a special milestone - the 25th time we are all coming together as a community!

Read more
View all news Subscribe